• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

良性乳腺疾病增加乳腺癌风险,与潜在家族风险特征无关:前瞻性家族研究队列的研究结果。

Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort.

机构信息

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.

Centre for Epidemiology and Biostatistics, The University of Melbourne, Parkville, VIC, Australia.

出版信息

Int J Cancer. 2019 Jul 15;145(2):370-379. doi: 10.1002/ijc.32112. Epub 2019 Feb 20.

DOI:10.1002/ijc.32112
PMID:30725480
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC6525034/
Abstract

Benign breast disease (BBD) is an established breast cancer (BC) risk factor, but it is unclear whether the magnitude of the association applies to women at familial or genetic risk. This information is needed to improve BC risk assessment in clinical settings. Using the Prospective Family Study Cohort, we used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of BBD with BC risk. We also examined whether the association with BBD differed by underlying familial risk profile (FRP), calculated using absolute risk estimates from the Breast Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model. During 176,756 person-years of follow-up (median: 10.9 years, maximum: 23.7) of 17,154 women unaffected with BC at baseline, we observed 968 incident cases of BC. A total of 4,704 (27%) women reported a history of BBD diagnosis at baseline. A history of BBD was associated with a greater risk of BC: HR = 1.31 (95% CI: 1.14-1.50), and did not differ by underlying FRP, with HRs of 1.35 (95% CI: 1.11-1.65), 1.26 (95% CI: 1.00-1.60), and 1.40 (95% CI: 1.01-1.93), for categories of full-lifetime BOADICEA score <20%, 20 to <35%, ≥35%, respectively. There was no difference in the association for women with BRCA1 mutations (HR: 1.64; 95% CI: 1.04-2.58), women with BRCA2 mutations (HR: 1.34; 95% CI: 0.78-2.3) or for women without a known BRCA1 or BRCA2 mutation (HR: 1.31; 95% CI: 1.13-1.53) (p  = 0.95). Women with a history of BBD have an increased risk of BC that is independent of, and multiplies, their underlying familial and genetic risk.

摘要

良性乳腺疾病(BBD)是已确定的乳腺癌(BC)风险因素,但尚不清楚这种关联的程度是否适用于具有家族性或遗传性风险的女性。这些信息对于提高临床环境中的 BC 风险评估是必要的。使用前瞻性家族研究队列,我们使用 Cox 比例风险模型来估计 BBD 与 BC 风险之间的关联的风险比(HR)和 95%置信区间(CI)。我们还检查了 BBD 与潜在家族风险特征(FRP)之间的关联是否不同,该特征是使用来自乳腺卵巢疾病发病和携带者估计算法(BOADICEA)模型的绝对风险估计计算得出的。在 176756 名女性(中位随访时间:10.9 年,最长随访时间:23.7 年)中,这些女性在基线时均未患有 BC,我们观察到 968 例 BC 发病病例。共有 4704 名(27%)女性在基线时报告了 BBD 诊断史。BBD 病史与更高的 BC 风险相关:HR=1.31(95%CI:1.14-1.50),并且与潜在的 FRP 无关,各分类的 HR 值分别为 1.35(95%CI:1.11-1.65)、1.26(95%CI:1.00-1.60)和 1.40(95%CI:1.01-1.93),分别对应 BOADICEA 评分的全生命周期<20%、20-<35%和≥35%类别。BRCA1 突变(HR:1.64;95%CI:1.04-2.58)、BRCA2 突变(HR:1.34;95%CI:0.78-2.3)或没有已知 BRCA1 或 BRCA2 突变的女性(HR:1.31;95%CI:1.13-1.53)(p=0.95)之间的相关性没有差异。有 BBD 病史的女性患 BC 的风险增加,且这种风险独立于其潜在的家族性和遗传性风险,并使这些风险倍增。

相似文献

1
Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort.良性乳腺疾病增加乳腺癌风险,与潜在家族风险特征无关:前瞻性家族研究队列的研究结果。
Int J Cancer. 2019 Jul 15;145(2):370-379. doi: 10.1002/ijc.32112. Epub 2019 Feb 20.
2
Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC).饮酒、吸烟与家族性乳腺癌风险:前瞻性家族研究队列(ProF-SC)的研究结果。
Breast Cancer Res. 2019 Nov 28;21(1):128. doi: 10.1186/s13058-019-1213-1.
3
Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.BRCA1或BRCA2基因已知家族突变检测呈阴性的个体患乳腺癌的风险
Breast Cancer Res Treat. 2010 Jan;119(2):409-14. doi: 10.1007/s10549-009-0611-y.
4
The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?BRCA1/2 基因突变携带者的癌症家族史与卵巢癌风险的关联:能否用突变位置来解释?
Eur J Hum Genet. 2018 Jun;26(6):848-857. doi: 10.1038/s41431-018-0111-9. Epub 2018 Feb 26.
5
Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.BRCA1/2 基因突变携带者和非携带者在前瞻性强化监测下的乳腺癌风险。
Int J Cancer. 2020 Feb 15;146(4):999-1009. doi: 10.1002/ijc.32396. Epub 2019 May 22.
6
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.BRCA1 或 BRCA2 基因突变女性的癌症家族史和癌症风险。
J Natl Cancer Inst. 2010 Dec 15;102(24):1874-8. doi: 10.1093/jnci/djq443. Epub 2010 Nov 23.
7
Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.BRCA相关乳腺癌的临床与分子特征:丹麦乳腺癌协作组的研究结果
Acta Oncol. 2018 Jan;57(1):95-101. doi: 10.1080/0284186X.2017.1398415. Epub 2017 Nov 22.
8
Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.评估 BOADICEA 风险评估模型在有乳腺癌家族史的女性中的应用。
Fam Cancer. 2012 Mar;11(1):33-40. doi: 10.1007/s10689-011-9495-1.
9
Evaluation of 2 breast cancer risk models in a benign breast disease cohort.评估 2 种乳腺癌风险模型在良性乳腺疾病队列中的表现。
Cancer. 2018 Aug;124(16):3319-3328. doi: 10.1002/cncr.31528. Epub 2018 Jun 22.
10
Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.乳腺钼靶筛查与BRCA1和BRCA2突变携带者患乳腺癌的风险:一项前瞻性研究。
Breast Cancer Res Treat. 2014 Aug;147(1):113-8. doi: 10.1007/s10549-014-3063-y. Epub 2014 Aug 1.

引用本文的文献

1
Breast biopsies and breast cancer risk in Israeli BRCA germline pathogenic variant carriers.以色列BRCA种系致病变异携带者的乳腺活检与乳腺癌风险
Breast Cancer Res Treat. 2025 Jul 22. doi: 10.1007/s10549-025-07787-3.
2
Plasma-derived exosomal human epidermal growth factor receptor 2 (HER2) protein for distinguishing breast cancer from benign breast disease and assessing the efficacy of neoadjuvant therapy.血浆来源的外泌体人表皮生长因子受体2(HER2)蛋白用于区分乳腺癌与乳腺良性疾病及评估新辅助治疗疗效
Transl Cancer Res. 2025 May 30;14(5):3186-3200. doi: 10.21037/tcr-2025-825. Epub 2025 May 27.
3
Subsequent percutaneous breast biopsies after initial atypia diagnosis: The patient burden of long-term follow up.

本文引用的文献

1
Evaluation of 2 breast cancer risk models in a benign breast disease cohort.评估 2 种乳腺癌风险模型在良性乳腺疾病队列中的表现。
Cancer. 2018 Aug;124(16):3319-3328. doi: 10.1002/cncr.31528. Epub 2018 Jun 22.
2
Clinicopathologic features of breast cancers that develop in women with previous benign breast disease.既往有良性乳腺疾病的女性所患乳腺癌的临床病理特征。
Cancer. 2016 Feb 1;122(3):378-85. doi: 10.1002/cncr.29766. Epub 2015 Oct 29.
3
Impact of preventive therapy on the risk of breast cancer among women with benign breast disease.
初次诊断为非典型增生后进行的后续经皮乳房活检:长期随访给患者带来的负担
Am J Surg. 2025 Jan;239:115993. doi: 10.1016/j.amjsurg.2024.115993. Epub 2024 Sep 27.
4
The relationship between demographic factors and known risk factors with breast cancer in women aged 30-69.30至69岁女性的人口统计学因素及已知风险因素与乳腺癌之间的关系。
Ann Med Surg (Lond). 2024 May 6;86(7):3945-3953. doi: 10.1097/MS9.0000000000002114. eCollection 2024 Jul.
5
Benign Breast Disease and Breast Cancer Risk in the Percutaneous Biopsy Era.经皮活检时代的良性乳腺疾病与乳腺癌风险。
JAMA Surg. 2024 Feb 1;159(2):193-201. doi: 10.1001/jamasurg.2023.6382.
6
Precise, Genotype-First Breast Cancer Prevention: Experience With Transferring Monogenic Findings From a Population Biobank to the Clinical Setting.精准的、基因型优先的乳腺癌预防:将单基因研究结果从人群生物样本库转化至临床实践的经验
Front Genet. 2022 Jul 22;13:881100. doi: 10.3389/fgene.2022.881100. eCollection 2022.
7
Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evaluation of the weight, physical activity, and alcohol consumption recommendations.遵循 2020 年美国癌症协会癌症预防指南和乳腺癌家族登记处中家族性和遗传性风险增加的女性乳腺癌风险:对体重、身体活动和饮酒建议的评估。
Breast Cancer Res Treat. 2022 Aug;194(3):673-682. doi: 10.1007/s10549-022-06656-7. Epub 2022 Jul 2.
8
A Multicentre Observational Study on Risk Factors for Breast Cancer.一项关于乳腺癌危险因素的多中心观察性研究。
J Obstet Gynaecol India. 2020 Oct;70(5):371-375. doi: 10.1007/s13224-020-01330-8. Epub 2020 Jul 10.
9
Commentary: No multiplicative GXE interactions for breast cancer risk: Have we reached a verdict or is the jury still out?评论:乳腺癌风险不存在基因-环境相互作用的倍增效应:我们已经得出结论了,还是仍有待进一步裁决?
Int J Epidemiol. 2020 Feb 1;49(1):231-232. doi: 10.1093/ije/dyz258.
10
Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC).饮酒、吸烟与家族性乳腺癌风险:前瞻性家族研究队列(ProF-SC)的研究结果。
Breast Cancer Res. 2019 Nov 28;21(1):128. doi: 10.1186/s13058-019-1213-1.
预防性治疗对患有良性乳腺疾病的女性患乳腺癌风险的影响。
Breast. 2015 Nov;24 Suppl 2(Suppl 2):S51-5. doi: 10.1016/j.breast.2015.07.013.
4
Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC).队列简介:乳腺癌前瞻性家族研究队列(ProF-SC)。
Int J Epidemiol. 2016 Jun;45(3):683-92. doi: 10.1093/ije/dyv118. Epub 2015 Jul 13.
5
Breast cancer risk associated with benign breast disease: systematic review and meta-analysis.与乳腺良性疾病相关的乳腺癌风险:系统评价与荟萃分析
Breast Cancer Res Treat. 2015 Feb;149(3):569-75. doi: 10.1007/s10549-014-3254-6. Epub 2015 Jan 31.
6
Atypical hyperplasia of the breast--risk assessment and management options.乳腺非典型增生——风险评估与管理选择
N Engl J Med. 2015 Jan 1;372(1):78-89. doi: 10.1056/NEJMsr1407164.
7
BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.BOADICEA 乳腺癌风险预测模型:癌症发病率、肿瘤病理学和网络界面更新。
Br J Cancer. 2014 Jan 21;110(2):535-45. doi: 10.1038/bjc.2013.730. Epub 2013 Dec 17.
8
A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer.多中心前瞻性队列研究良性乳腺疾病与后续乳腺癌风险。
Cancer Causes Control. 2010 Jun;21(6):821-8. doi: 10.1007/s10552-010-9508-7. Epub 2010 Jan 19.
9
Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease.IGF-I和IGFBP-3的基因变异及循环水平与增殖性良性乳腺疾病风险的关系
Int J Cancer. 2010 Jan 1;126(1):180-90. doi: 10.1002/ijc.24674.
10
Where's the outrage?义愤何在?
J Am Coll Surg. 2009 Jan;208(1):78-9. doi: 10.1016/j.jamcollsurg.2008.09.022.